GlassScriptPhysician profile
John T Sentz
NPI 1497074561
$19,603.57
in general payments reported to CMS, 2019-2025
37 companies · $6,133 in 2025
The $6,133 reported for 2025 was more than what 90% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $332 · 2021: $1,673 · 2022: $2,092 · 2023: $2,437 · 2024: $6,664 · 2025: $6,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,920 · Education: $4,327 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,250 · Travel and Lodging: $736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,920.00 |
| Education | $4,327.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,250.00 |
| Travel and Lodging | $735.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,788.79 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Intuitive Surgical, INC. | $4,805.09 | 2024 | |
| Glaxosmithkline, LLC. | $1,775.67 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $678.78 | 2021-2025 | Tezspire, Tavneos |
| Actelion Pharmaceuticals US, INC. | $621.25 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Grifols USA, LLC | $601.15 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $549.07 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $532.93 | 2019-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $460.21 | 2020-2024 | Acthar |
| Genentech USA, INC. | $452.37 | 2021-2025 | Xolair |
| Genzyme Corporation | $447.17 | 2021-2025 | |
| Insmed, INC. | $353.04 | 2021-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $307.37 | 2021-2024 | Yupelri |
| Ani Pharmaceuticals, INC. | $306.24 | 2023-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $294.68 | 2021-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $274.05 | 2020-2025 | Tyvaso, Tyvaso, Remodulin |
| Takeda Pharmaceuticals U.S.A., INC. | $219.76 | 2021-2025 | Glassia |
| Pfizer INC. | $211.63 | 2021-2025 | |
| Electromed, INC. | $153.47 | 2021-2023 | Smartvest |
| Merck Sharp & Dohme LLC | $148.15 | 2019-2024 | Winrevair, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $110.30 | 2019-2025 | |
| Inogen, INC. | $64.27 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Sanofi-Aventis U.S. LLC | $57.48 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $55.05 | 2020-2022 | |
| Philips North America LLC | $47.20 | 2019-2022 | |
| Baxter Healthcare | $41.81 | 2024 | Hillrom - Monarch Airway Clearance System |
| Covidien LP | $39.56 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $36.35 | 2019 | |
| Paratek Pharmaceuticals, INC. | $26.86 | 2021 | |
| Atricure, INC. | $25.58 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| La Jolla Pharmaceutical Company | $24.48 | 2022 | |
| Axsome Therapeutics, INC. | $18.00 | 2023 | Sunosi |
| Covis Pharma Gmbh | $17.04 | 2022 | |
| Vifor Pharma, INC. | $16.29 | 2019 | |
| Viatris Specialty LLC | $16.10 | 2025 | Yupelri |
| Pulmonx Corporation | $14.09 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Sandoz INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sentz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.